Clinical Trial Update: Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of liposomal doxorubicin combined with docetaxel in HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Catharina Ziekenhuis Eindhoven | Conditions: Breast Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED